Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antipsychotic
Biotech
Reviva’s drug reduces symptoms in year-long schizophrenia study
Reviva was testing brilaroxazine, an antipsychotic and dopamine-serotonin system modulator, in the open-label extension of the ongoing RECOVER study.
James Waldron
Dec 16, 2024 10:29am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Karuna's journey from 'serendipitous clinical finding' to FDA
Oct 4, 2023 6:00am
Cerevel stock doubles on success of phase 1b schizophrenia trial
Jun 30, 2021 7:15am
Acadia adds pain meds to the pipeline with $52.5M CerSci buyout
Aug 25, 2020 3:57pm
Could I-O drugs get a boost from an existing antipsychotic drug?
Mar 6, 2020 9:30am
